Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

医学 腹水 肝硬化 内科学 危险系数 临床终点 随机对照试验 意向治疗分析 白蛋白 胃肠病学 临床试验 置信区间 外科
作者
Paolo Caraceni,Oliviero Riggio,Paolo Angeli,Carlo Alessandria,Sergio Neri,Francesco Giuseppe Foschi,Fabio Levantesi,Aldo Airoldi,Sergio Boccia,Gianluca Svegliati‐Baroni,S. Fagiuoli,Roberto Giulio Romanelli,Raffaele Cozzolongo,V. Di Marco,Vincenzo Sangiovanni,Filomena Morisco,Pierluigi Toniutto,A. Tortora,Rosanna De Marco,M. Angélico
出处
期刊:The Lancet [Elsevier BV]
卷期号:391 (10138): 2417-2429 被引量:425
标识
DOI:10.1016/s0140-6736(18)30840-7
摘要

Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly) for up to 18 months. The primary endpoint was 18-month mortality, evaluated as difference of events and analysis of survival time in patients included in the modified intention-to-treat and per-protocol populations. This study is registered with EudraCT, number 2008–000625–19, and ClinicalTrials.gov, number NCT01288794. Findings From April 2, 2011, to May 27, 2015, 440 patients were randomly assigned and 431 were included in the modified intention-to-treat analysis. 38 of 218 patients died in the SMT plus HA group and 46 of 213 in the SMT group. Overall 18-month survival was significantly higher in the SMT plus HA than in the SMT group (Kaplan-Meier estimates 77% vs 66%; p=0·028), resulting in a 38% reduction in the mortality hazard ratio (0·62 [95% CI 0·40–0·95]). 46 (22%) patients in the SMT group and 49 (22%) in the SMT plus HA group had grade 3–4 non-liver related adverse events. Interpretation In this trial, long-term HA administration prolongs overall survival and might act as a disease modifying treatment in patients with decompensated cirrhosis. Funding Italian Medicine Agency.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ccalvintan发布了新的文献求助10
1秒前
1秒前
2秒前
MchemG应助闲听松风眠采纳,获得10
2秒前
2秒前
2秒前
2秒前
NexusExplorer应助灵巧鑫采纳,获得30
3秒前
3秒前
共享精神应助鲤跃采纳,获得10
4秒前
SYLH应助橙子采纳,获得20
4秒前
特安谭完成签到,获得积分10
4秒前
5秒前
RoKing完成签到,获得积分10
5秒前
ding完成签到,获得积分10
6秒前
胡志飞发布了新的文献求助10
6秒前
科研通AI2S应助嗷嗷采纳,获得10
6秒前
zzz发布了新的文献求助10
7秒前
深情安青应助好宝宝采纳,获得10
7秒前
7秒前
7秒前
7秒前
8秒前
Noah完成签到 ,获得积分10
8秒前
SciGPT应助大冰采纳,获得10
8秒前
量子星尘发布了新的文献求助80
8秒前
天边发布了新的文献求助10
9秒前
未央歌完成签到 ,获得积分10
9秒前
9秒前
Xinger完成签到,获得积分10
10秒前
11秒前
sssaw发布了新的文献求助10
11秒前
RoKing发布了新的文献求助10
12秒前
香蕉觅云应助zy采纳,获得10
12秒前
Xinger发布了新的文献求助10
13秒前
xiaozhiok发布了新的文献求助10
13秒前
思垢发布了新的文献求助10
13秒前
14秒前
zjh完成签到,获得积分10
15秒前
16秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988732
求助须知:如何正确求助?哪些是违规求助? 3531027
关于积分的说明 11252281
捐赠科研通 3269732
什么是DOI,文献DOI怎么找? 1804764
邀请新用户注册赠送积分活动 881869
科研通“疑难数据库(出版商)”最低求助积分说明 809021